DIAGNOS Announces the Creation of Indian Subsidiary and the Opening of an Office in India

BROSSARD, QUEBEC--(Marketwired - Sept. 18, 2013) - DIAGNOS inc. ("DIAGNOS" or "the Corporation") (TSX VENTURE:ADK), leader in healthcare technical services including, screening, software and algorithm development, data analysis, and image processing, announces today the Creation of Indian Subsidiary and the Opening of an Office in Mumbai, India, to support and coordinate deployment and usage of CARA in India.

To execute on the LOI signed with a major global pharmaceutical company in India, announced on September 4^th 2013, Diagnos has created a local subsidiary: DIAGNOS HEALTHCARE (INDIA) PRIVATE LIMITED. The subsidiary is incorporated in Mumbai, Maharashtra, India, under the Indian Companies Act, as a private limited company approved by ANURADHA BHASKAR ATHAVALE, Deputy Registrar of Companies.

The official Indian address as per record deposited and available in the Indian Registrar of Companies office is:

DIAGNOS HEALTHCARE (INDIA) PRIVATE LIMITED

Platinum Techno Park 17 & 18, Level 13,

Sector 30 Vashi, Navi Mumbai, 400705, Maharashtra, INDIA

"The Mumbai office will serve as a coordination centre for Mumbai, and New Delhi mobile screening units (comprising our CARA platform, screening van, licensed optometric screener, and driver), which will initially cover territories with 500km radius around the respective cities, and traveling to cities, towns, and villages in the designated coverage areas to conduct mobile screening camps in association with participating primary and tertiary healthcare institutions. Our India office will also serve as a coordination point for activities in the broader region, which will comprise India and the Middle East." Said Peter Nowacki, Diagnos' Vice-President - Healthcare.

About CARA

CARA is a tele-ophthalmology platform that integrates with ophthalmic imaging equipment (hardware and software) and processes at the point of care (POC) and comprises: image upload, image enhancement automated pre-screening, grading by a specialist, and referral to a specialist. CARA's image enhancement algorithms make standard retinal images sharper, clearer, and easier to read. CARA is accessible securely over the internet, and is compatible with all recognized image formats and brands of fundus cameras, and is EMR compatible. CARA is a cost-effective tool for screening large numbers of patients, in real-time and has been approved by regulatory authorities including Health Canada, US Food and Drug Administration, and the European Union.

About DIAGNOS

Founded in 1998, DIAGNOS is a publicly traded Canadian corporation with a mission to commercialize technologies combining contextual imaging and traditional data mining thereby improving decision making processes. DIAGNOS offers products, services, and solutions to clients in a variety of fields including healthcare and natural resources.

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For further information on DIAGNOS, please visit our website at www.diagnos.com or the SEDAR website at www.sedar.com.